SABCS 2024 | Characterizing genetic mutations with NGS in breast cancer brain metastases

Gaia Griguolo • 13 Dec 2024

SABCS 2024

Breast Cancer

Gaia Griguolo, MD, University of Padova, Padova, Italy, highlights findings from a study which focused on the molecular characterization of brain metastases tissue with next-generation sequencing (NGS) in patients with breast cancer to identify clinically actionable genomic alterations with the ESCAT scale (ESMO Scale for Clinical Actionability of molecular Targets). More than 60% of the mutations were clinically actionable, of which HRD mutations were most prevalent in triple-negative breast cancer. A 20% rate of HRD alterations were seen in the homo-receptor HER2+ breast cancer. This interview took place at 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.